Astrid van der Veldt

27PUBLICATIONS
93CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Respiratory diseasesApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Epidemiological modellingPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (27)

|Dec 26, 2025
Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma.

Ruben Malmberg, Maaike M Hofman, Fatima Ashad

|Oct 15, 2025
COVID-19 Vaccine Effectiveness in Patients With Hematologic Malignancies: A Nationwide Cohort Study.

Quincy Hofsink, Birgit I Lissenberg-Witte, Sabine Haggenburg

|Apr 28, 2025
Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy.

E J van Dijk, H H Nienhuis, A J M van den Eertwegh

|Apr 15, 2025
Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis.

M Bloem, M M de Meza, A J M van den Eertwegh

|Mar 07, 2025
Size matters: Early progression of melanoma brain metastases after treatment with immune checkpoint inhibitors.

Sophie H A E Derks, Li Shen Ho, Stephan R Koene

|Feb 22, 2025
Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma.

Saskia de Groot, Hedwig M Blommestein, Brenda Leeneman

Pageof 5